iRadimed (IRMD) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- $0.55
- Surprise
- —
- Score today
- 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- iRadimed Reports Q3 2026 Financial Results and Provides Updated Outlook — fiscal.ai, 2026-10-30
- iRadimed Narrows FY2026 GAAP EPS Guidance from $1.90-$2.05 to $1.90-$1.94 vs $1.94 Est — benzinga, 2026-10-30
- iRadimed Lowers FY2026 Adj EPS Guidance from $2.09-$2.24 to $2.07-$2.11 vs $2.11 Est; Narrows FY2026 Sales Guidance from — benzinga, 2026-10-30
Where TrendMatrix's rating stands now
TrendMatrix currently rates IRMD Hold at 5.3/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.8 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: MRidium infusion pumps and 3880 monitoring system
- Concentration risk — Supplier: single-source suppliers
- Earnings estimates trending DOWN
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $85.74
- Price target
- $100.30
- Stop
- $81.74
- Upside to target
- +17.0%
- Reward-to-risk
- 3.4:1
The stock trades at 47.9× trailing but 34.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
IRMD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.10B
- P/E (fwd)
- 34.9
- P/E (ttm)
- 47.9
- 52-week range
- $75.75–$107.90
- Off 52-week high
- 20.5%
- RSI (14)
- 42
- Volume vs avg
- 0.88×
- Score today
- 5.3/10